Talk:MDAT: Difference between revisions
m Signing comment by 82.24.103.156 - "" |
No edit summary |
||
Line 12: | Line 12: | ||
'''3b fully substituted in MDMA-trained rats''' |
'''3b fully substituted in MDMA-trained rats''' |
||
6,7-(methylenedioxy)-2-aminotetralin substitues for MDMA in rats 5,6-(methylenedioxy)-2-aminotetralin DOES NOT |
6,7-(methylenedioxy)-2-aminotetralin substitues for MDMA in rats 5,6-(methylenedioxy)-2-aminotetralin DOES NOT --[[User:Rollie|Rollie]] ([[User talk:Rollie|talk]]) 11:33, 2 June 2010 (UTC) |
Revision as of 11:33, 2 June 2010
Pharmacology Unassessed | ||||||||||
|
Chemicals Stub‑class Low‑importance | ||||||||||
|
I rewort the article because although there was a source, the info in the wiki page was completely contradictory to the results of the rat study. This is most likely because it is being sold as a research chemical, and vendors want to make it seem worthwhil to purchase. I will quote the lines that prove this:
6,7- and 5,6-(methylenedioxy)-2-aminotetralin (3b and 4b, respectively) were tested for stimulus generalization in the two-lever drug-discrimination paradigm (5,6-(methylenedioxy)-2-aminotetralin is MDAT, called 4b in the study)
Now the results: Compounds 4a and 4b did not substitute in MDMA-trained rats
HOWEVER 3b fully substituted in MDMA-trained rats
6,7-(methylenedioxy)-2-aminotetralin substitues for MDMA in rats 5,6-(methylenedioxy)-2-aminotetralin DOES NOT --Rollie (talk) 11:33, 2 June 2010 (UTC)